
- /
- Supported exchanges
- / US
- / AMRN.NASDAQ
Amarin Corporation PLC (AMRN NASDAQ) stock market data APIs
Amarin Corporation PLC Financial Data Overview
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin 2, Ireland.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Amarin Corporation PLC data using free add-ons & libraries
Get Amarin Corporation PLC Fundamental Data
Amarin Corporation PLC Fundamental data includes:
- Net Revenue: 214 M
- EBITDA: -55 514 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-18
- EPS/Forecast: -0.4
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Amarin Corporation PLC News

European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
European equities traded in the US as American depositary receipts were modestly higher late Thursda PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...


Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU
Shares of Amarin AMRN jumped 27.3% on Tuesday after the company announced that it has signed an exclusive long-term license and supply agreement with Italy-based Recordati to commercialize its sole ma...

Amarin (AMRN) Soars 27.3%: Is Further Upside Left in the Stock?
Amarin (AMRN) shares rallied 27.3% in the last trading session to close at $16.04. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session...

Amarin Grants Recordati Exclusive Rights To Commercialize VAZKEPA Across 59 European Countries
(RTTNews) - Amarin Corporation (AMRN) has entered a long-term exclusive license and supply agreement with Italian pharmaceutical firm Recordati S.p.A. to commercialize VAZKEPA (icosapent ethyl) in 59 ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.